# Special Issue

# Personalized Medicine in Psychiatry: Challenges and Opportunities

## Message from the Guest Editor

I am thrilled to extend a warm invitation for you to contribute your manuscripts to our Special Issue, "Personalized Medicine in Psychiatry: Challenges and Opportunities", within the esteemed Journal of Personalized Medicine. We welcome you to embark on a collaborative interdisciplinary journey with us. We are eager to receive contributions that delve into the realms of the cutting-edge research, innovative methodologies, and insightful perspectives that are reshaping the boundaries of psychiatric care. Whether you are unraveling the genetic basis of mental health disorders or exploring the impact of biomarkers on treatment response, your work is crucial to fostering a vibrant dialogue among researchers, clinicians, and stakeholders. Let us not forget the importance of public health and epidemiology research—without real-world data, personalized medicine would not be the force it is today. Join us in this exciting intellectual endeavor. Your insights and expertise will be shaping the future of personalized medicine in psychiatry. We look forward to your invaluable contribution.

#### **Guest Editor**

Dr. Gniewko Więckiewicz

Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland

## Deadline for manuscript submissions

20 April 2025



# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/196234

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



# About the Journal

### Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

#### Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

